Both biosimilar and generic drugs have an abbreviated approval process; however, the clinical trial requirements differ enormously.
Keith Watson
Advertisement
Keith Watson is a Principal Consultant at PAREXEL Consulting.
Articles by Keith Watson
Advertisement
Latest Updated Articles
- Clinical And Cost Considerations Of Developing A Biosimilar
Published: September 1st 2010 | Updated:
Advertisement
Advertisement
